IRVINE, October 19, 2010 – ALLIANCE MEDICAL PRODUCTS, INC. (“AMP”) announced today it has received commercial approval of its automated IMA tube filling line. The line will be put to use immediately for the commercial manufacture of a sterile ophthalmic ointment recently approved by the FDA.

“The approval of this drug and AMP’s automated IMA tube filling line further solidifies our company's reputation as the industry’s leading cGMP supplier of difficult to manufacture formulations,” said Juan Valdes, President and CEO. “ The IMA line has a capacity of 30,000 tubes per shift with tube size diameters ranging 10 to 60 mm with volumes ranging from 1 to 50 grams.” The line will be used primarily to fill sterile gels, creams and ointments.

“AMP’s innovative process design expertise was a key factor in achieving these approvals. These approvals open a new door for us, as we see nasal and otic drug products pushed into sterile filling along with ophthalmics which have long been packaged sterile.” said Valdes.

 ALLIANCE MEDICAL PRODUCTS, INC. is a full service cGMP, FDA and ISO13485 drug, device and combination product contract manufacturer providing developmental, clinical and commercial contract manufacturing services to large and small organizations. AMP specializes in difficult to manufacture formulations that include solutions, suspensions, emulsions, sterile ointments and gels with the capability to fill an array of container closures including vials, dropper tip bottles, screw cap bottles, cartridges and squeeze tubes.  AMP has extensive manufacturing capabilities which include four high volume automated aseptic filling suites and three semi-automated low volume aseptic filling suites.  In addition to its manufacturing capabilities, AMP maintains state of the art micro and analytical laboratories, and the capability to provide stability services meeting all ICH guidelines.

If you’d like more information about AMP, or to schedule a meeting, please contact Steve Tulk at 949-454-4582 or email Steve at This e-mail address is being protected from spambots. You need JavaScript enabled to view it